BioCentury | May 26, 2020
Distillery Therapeutics

Blocking inhibitor of apoptosis proteins in liver cells to treat malaria

DISEASE CATEGORY: Infectious disease INDICATION: Malaria Targeting IAP, a family of apoptosis-blocking proteins that includes BIRC2 and BIRC3, could treat malaria by clearing liver infection. In mice infected with Plasmodium berghei sporozoites, the parasite stage...
BioCentury | Oct 4, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer; leukemia Cell culture, mouse and patient-derived organoid studies identified a benzothiophene-benzothiazole-based BIRC2 inhibitor that could help treat breast cancer and leukemias. Screening of 50,000 small molecules in BIRC2 enzymatic activity assays yielded...
BioCentury | May 25, 2018
Clinical News

MimiVax reports Phase II data for glioblastoma immunotherapy

...Cancer Center, which discovered SurVaxM. SurVaxM is an immunotherapy comprising SVN53-67/M57-KLH, a peptide mimic targeting survivin (BIRC5)...
...Product: SurVaxM Business: Cancer Molecular target: Survivin (BIRC5) Description: Immunotherapy comprising SVN53-67/M57-KLH, a peptide mimic targeting BIRC5...
...Phase II data Milestone: Final Phase II data (4Q18) Sandi Wong SurVaxM (DRU-2017-5947) American Society of Clinical Oncology MimiVax LLC Survivin (BIRC5)...
BioCentury | May 11, 2018
Clinical News

Medigene reports Phase I/II data for prostate cancer vaccine

...comprises autologous monocyte-derived dendritic cells targeting PSA combined with human telomerase reverse transcriptase (TERT) and survivin (BIRC5)...
...Description: Autologous monocyte-derived dendritic cells targeting PSA combined with human telomerase reverse transcriptase (TERT) and survivin (BIRC5)...
...data Milestone: NA Jaime De Leon DC vaccine targeting PSA American Association for Cancer Research Medigene AG Prostate-specific antigen (PSA) (KLK3) Survivin (BIRC5) Telomerase...
BioCentury | Mar 9, 2018
Financial News

Oxford Vacmedix raises $12.5M series A

...and solid tumors, respectively. OVM-100 is an HPV vaccine, and OVM-200 is a vaccine using survivin (BIRC5)...
BioCentury | Mar 6, 2018
Financial News

Oxford Vacmedix raises $12.5M series A

...and solid tumors, respectively. OVM-100 is an HPV vaccine, and OVM-200 is a vaccine using survivin (BIRC5)...
BioCentury | Mar 1, 2018
Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...
BioCentury | Feb 9, 2018
Clinical News

Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer

...duration of response, time to progression and overall survival (OS). DPX-Survivac is a vaccine comprising survivin (BIRC5)-based...
...TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia Product: DPX-Survivac Business: Cancer Molecular target: Survivin (BIRC5) Description: Vaccine comprising BIRC5-based...
...Status: Phase Ib data Milestone: Updated Phase Ib data (1H18) Jennie Walters DPX-Survivac epacadostat IMV Inc. Incyte Corp. Indoleamine 2,3-dioxygenase 1 (IDO1) Survivin (BIRC5)...
BioCentury | Dec 22, 2017
Clinical News

Stemline reports additional Phase II data for SL-701 in GBM

...short peptides against IL-13 receptor alpha 2 (IL-13RA2; IL-13R; CD213A2), EPH receptor A2 (EPHA2) and survivin (BIRC5)...
...receptor A2 (EPHA2); survivin (BIRC5) Description: Cancer immunotherapy comprising synthetic short peptides against IL-13RA2, EPHA2 and BIRC5...
... Allison Johnson SL-701 Stemline Therapeutics Inc. University of Pittsburgh EPH receptor A2 (EPHA2) Interleukin-13 (IL-13) receptor alpha 2 (IL-13RA2) (IL-13R) (CD213A2) Survivin (BIRC5) Society...
BioCentury | Sep 13, 2017
Distillery Therapeutics

Infectious disease

...inhibiting A. fumigatus BIR1 with a tool compound designed to inhibit the protein's human homolog, survivin (BIRC5)...
Items per page:
1 - 10 of 94